LTA and neoplasm: While infliximab and adalimumab are based on anti-TNF antibodies and bind only to TNF, etanercept is based on a TNFR-2-Ig fusion protein that can bind TNF and LTα [109], which could have consequences, since LTα potentially has a TNF-independent role in tumor control [121].